NMPA Adds 74 External Experts to Strengthen CE/FDA Submission Review

On April 29, 2026, the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) released its Third Batch of 2025 Supplemental List of External Experts, adding 74 specialists in clinical evaluation, EMC testing for active medical devices, and AI-based SaMD algorithm validation. This move signals heightened technical scrutiny for Chinese manufacturers exporting high-end imaging systems, surgical robots, and IVD analyzers—particularly concerning CE MDR and FDA 510(k) submissions—and underscores growing regulatory expectations around localized clinical data and algorithm interpretability documentation.

Event Overview

On April 29, 2026, the NMPA’s Center for Drug Evaluation published the Supplemental List of External Experts (Third Batch of 2025), confirming the addition of 74 external experts. The list explicitly identifies expertise domains including clinical evaluation, electromagnetic compatibility (EMC) testing for active medical devices, and verification of artificial intelligence software as a medical device (AI SaMD) algorithms. No further details—such as institutional affiliations, geographic distribution, or term durations—were disclosed in the official announcement.

Which Sub-Sectors Are Affected?

Direct Exporters of Medical Devices

Exporters targeting the EU and U.S. markets face intensified technical review expectations during CE MDR conformity assessment and FDA 510(k) clearance. Because the newly added experts specialize in clinical evaluation and AI algorithm validation, submissions for products such as surgical robots and AI-powered IVD analyzers may encounter more rigorous questioning on clinical relevance, real-world performance consistency, and transparency of model decision logic.

Manufacturers of High-End Active Devices

Producers of imaging equipment (e.g., MRI/CT systems), electrosurgical units, and other active devices are directly impacted by the inclusion of EMC testing specialists. Under CE MDR, EMC compliance is no longer treated as a standalone test but integrated into the broader risk management file. Enhanced expert capacity suggests greater scrutiny of test protocols, environmental simulation rigor, and post-market EMC-related incident analysis.

AI SaMD Developers and Algorithm Providers

Companies developing AI-driven diagnostic or therapeutic software must now anticipate deeper review of algorithm validation dossiers—not only for accuracy metrics but also for traceability, bias mitigation strategies, and human-readable explanations of model behavior. The CDE’s emphasis on ‘algorithm interpretability documentation’ implies alignment with FDA’s AI/ML Software as a Medical Device (SaMD) framework and EU MDR Annex XVI requirements.

What Should Relevant Enterprises or Practitioners Focus On—and How to Respond Now

Monitor Official Guidance Updates on Clinical Data Requirements

While the expert list itself contains no new policy language, it reflects a clear capacity-building step ahead of anticipated revisions to CDE’s technical guidance documents on clinical evaluation for export-oriented devices. Enterprises should track upcoming drafts—especially those addressing equivalence justification under CE MDR and real-world evidence use in FDA submissions.

Prioritize Documentation Readiness for Algorithm Transparency

For AI SaMD developers, current readiness efforts should focus on generating auditable, version-controlled documentation that explains input–output relationships, uncertainty quantification, and failure mode assumptions—not just statistical performance reports. This aligns with the newly emphasized ‘algorithm interpretability’ criterion.

Review EMC Test Protocols Against Notified Body Expectations

Manufacturers of active devices should re-evaluate their existing EMC test plans against latest EU harmonized standards (e.g., EN IEC 60601-1-2:2021) and FDA’s recommended practices. Internal audits should verify whether test conditions reflect actual intended use environments—including co-location with other hospital equipment and wireless interference scenarios.

Assess Local Clinical Data Gaps Early—Especially for Non-U.S./EU Markets

The CDE’s reinforcement of clinical evaluation expertise does not solely serve domestic review. It strengthens China’s ability to assess whether overseas clinical data meet local evidentiary thresholds for mutual recognition or bilateral cooperation frameworks. Exporters planning submissions in ASEAN, GCC, or LATAM markets should proactively map where local clinical studies—or bridging analyses—may soon be requested.

Editorial Perspective / Industry Observation

Observably, this expert expansion is less about immediate regulatory enforcement and more about institutional capacity building ahead of increasingly complex international submissions. Analysis shows the selection criteria—clinical evaluation, EMC, and AI SaMD—are precisely the three most contested technical areas in recent CE MDR audits and FDA pre-submission meetings. From an industry perspective, the move signals that China’s regulatory infrastructure is evolving toward parity in technical depth with major global authorities—not to replicate them, but to enable more robust, evidence-based dialogue during cross-border regulatory engagement. It is currently best understood as a preparatory signal rather than an operational trigger.

Current attention should therefore focus on how these experts influence upcoming guidance revisions—not on reactive compliance adjustments. Their presence increases the likelihood that future CDE feedback letters will reference internationally aligned benchmarks, making early alignment with ISO 14155, IEC 62304, and IMDRF AI/ML SaMD guidelines operationally advantageous.

Concluding, this update reflects a maturing phase in China’s medical device regulatory ecosystem—one where technical review capability is being deliberately scaled to match the sophistication of domestically developed products entering global markets. It does not introduce new obligations, but it does raise the bar for evidentiary quality expected in export dossiers. More accurately, it serves as a calibration point: enterprises whose clinical, EMC, and AI documentation already meet EU and U.S. expectations are better positioned to navigate both domestic review and international acceptance.

Source: Center for Drug Evaluation (CDE), National Medical Products Administration (NMPA), Supplemental List of External Experts (Third Batch of 2025), published April 29, 2026. No additional implementation timelines, guidance updates, or procedural changes were announced concurrently; these remain subjects for ongoing observation.